Immune thrombocytopenic purpura ( ITP )
Clinical trials for Immune thrombocytopenic purpura ( ITP ) explained in plain language.
Never miss a new study
Get alerted when new Immune thrombocytopenic purpura ( ITP ) trials appear
Sign up with your email to follow new studies for Immune thrombocytopenic purpura ( ITP ), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for teens with rare bleeding disorder: experimental drug enters final testing
Disease control Recruiting nowThis study tests an IV drug called efgartigimod in teens aged 12 to 18 with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bruising and bleeding. The goal is to find the right dose and see if it safely raises platelet counts…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA ( ITP )
Phase 2/3 • Sponsor: argenx • Aim: Disease control
Last updated Sep 21, 2026 22:00 UTC
-
New injection aims to stabilize platelets in chronic ITP patients
Disease control Recruiting nowThis Phase 3 trial tests whether mezagitamab, given as a shot under the skin, can safely keep platelet counts stable in adults with chronic ITP. ITP is a condition where the immune system destroys platelets, leading to easy bruising and bleeding. The study will compare mezagitama…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA ( ITP )
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New shot shows promise for Long-Term control of bleeding disorder
Disease control Recruiting nowThis study tests the long-term safety of a drug called mezagitamab for adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing easy bruising and bleeding. About 150 participants who completed earlier mezagitamab studies w…
Matched conditions: IMMUNE THROMBOCYTOPENIC PURPURA ( ITP )
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC